Barbara Troupin - Feb 14, 2025 Form 4 Insider Report for Equillium, Inc. (EQ)

Role
Director
Signature
/s/ Jason A. Keyes, Attorney-in-Fact
Stock symbol
EQ
Transactions as of
Feb 14, 2025
Transactions value $
$0
Form type
4
Date filed
2/19/2025, 07:30 PM
Previous filing
May 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EQ Director Stock Option (right to buy) Award +40K 40K Feb 14, 2025 Common Stock 40K $0.79 Direct F1, F2
transaction EQ Director Stock Option (right to buy) Disposed to Issuer -40K -100% 0 Feb 14, 2025 Common Stock 40K $3.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in 36 equal monthly installments following the grant date of March 1, 2022.
F2 On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.